Ajinomoto
Ajinomoto Co. is a leading global manufacturer based in Japan, specializing in seasonings, processed foods, beverages, amino acids, pharmaceuticals, and specialty chemicals. Known for its expertise in amino acid fermentation technologies, the company plays a significant role in enhancing food culture and promoting human health. Ajinomoto produces a variety of processed goods, including dry soup mixes and frozen foods, while also supplying monosodium glutamate (MSG) and nucleotides to major food producers worldwide. The food segment accounts for the majority of the company's sales and profits, with a significant portion generated from international markets. Additionally, Ajinomoto is focusing on healthcare and functional materials as key growth areas, aiming to address challenges related to food resources and global sustainability.
20 past transactions
Enhanced Medical Nutrition
Series A in 2025
Enhanced Medical Nutrition specializes in developing medical food products designed to enhance surgical outcomes through improved nutrition. The company focuses on research, development, and distribution of evidence-based clinical nutrition, particularly in the perioperative setting. Its offerings aim to support rehabilitation, promote wound healing, and manage the protein requirements of ill and aging individuals. By addressing nutritional needs, these products help patients reduce postoperative insulin resistance and facilitate a faster recovery process.
Safire Technology Group
Seed Round in 2024
Safire Technology Group specializes in developing lithium-ion electrolyte additive technology aimed at enhancing battery safety. Their innovative technology prevents explosions and fires by facilitating an immediate transformation from liquid to solid upon mechanical impact, thereby providing additional ballistic protection. This advancement allows clients to achieve safer, cost-effective, and higher-performing electric applications.
TechMagic
Series C in 2024
TechMagic is dedicated to enhancing daily life through the integration of artificial intelligence and robotics. The company focuses on the food industry with its primary project, which introduces cooking robots designed to automate cooking tasks in restaurant kitchens. By leveraging advanced technologies such as machine learning and robotics, TechMagic's solutions aim to significantly reduce labor costs for businesses. This innovation not only streamlines operations but also enhances productivity, allowing restaurant operators to optimize their workforce and improve overall efficiency.
Ajinomoto
Acquisition in 2023
Ajinomoto Co. is a leading global manufacturer based in Japan, specializing in seasonings, processed foods, beverages, amino acids, pharmaceuticals, and specialty chemicals. Known for its expertise in amino acid fermentation technologies, the company plays a significant role in enhancing food culture and promoting human health. Ajinomoto produces a variety of processed goods, including dry soup mixes and frozen foods, while also supplying monosodium glutamate (MSG) and nucleotides to major food producers worldwide. The food segment accounts for the majority of the company's sales and profits, with a significant portion generated from international markets. Additionally, Ajinomoto is focusing on healthcare and functional materials as key growth areas, aiming to address challenges related to food resources and global sustainability.
Ascend Gene & Cell Therapies
Series A in 2023
Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.
Sarah
Series D in 2023
SARAH Inc. is a Tokyo-based company that operates a mobile application designed for discovering and sharing restaurant menu pictures. Founded in 2014, the application, also named "SARAH," allows users to search for specific food items from various menus and post recommendations about their dining experiences. By facilitating menu-based searches, SARAH provides a platform where users can explore diverse culinary options and find restaurants that match their preferences. The application aims to enhance the dining experience by enabling users to connect with a community centered around food and restaurant-related information.
Tsubame BHB
Series B in 2022
Tsubame BHB Co., Ltd., founded in 2017 and based in Tokyo, Japan, specializes in the research, development, and manufacturing of on-site ammonia production systems and catalysts. The company aims to commercialize ammonia production using an innovative electride catalyst in small-scale plants. This technology addresses critical environmental and food-related issues while promoting sustainability. By enabling on-site ammonia synthesis under flexible conditions, Tsubame BHB helps clients lower their transportation and storage costs, contributing to a more efficient and sustainable ammonia supply chain.
On The Slope
Series G in 2021
On the way to Sakano deliver vegetables grown without the use of pesticides and chemical fertilizers, aiming to spread agriculture with low environmental impact. We want to make agriculture sustainable and reach a sustainable society.
Granules OmniChem Private Limited
Acquisition in 2020
Granules OmniChem Private Limited is a pharmaceutical company that specializes in contract development and active pharmaceutical ingredient (API) manufacturing services. Established in 2011 and headquartered in Visakhapatnam, India, the company operates as a joint venture between Granules India Limited and S.A. Ajinomoto OmniChem N.V. As of May 2020, it functions as a subsidiary of S.A. Ajinomoto OmniChem N.V., focusing on providing high-quality services in the pharmaceutical sector.
Tsubame BHB
Seed Round in 2020
Tsubame BHB Co., Ltd., founded in 2017 and based in Tokyo, Japan, specializes in the research, development, and manufacturing of on-site ammonia production systems and catalysts. The company aims to commercialize ammonia production using an innovative electride catalyst in small-scale plants. This technology addresses critical environmental and food-related issues while promoting sustainability. By enabling on-site ammonia synthesis under flexible conditions, Tsubame BHB helps clients lower their transportation and storage costs, contributing to a more efficient and sustainable ammonia supply chain.
Tsubame BHB
Seed Round in 2019
Tsubame BHB Co., Ltd., founded in 2017 and based in Tokyo, Japan, specializes in the research, development, and manufacturing of on-site ammonia production systems and catalysts. The company aims to commercialize ammonia production using an innovative electride catalyst in small-scale plants. This technology addresses critical environmental and food-related issues while promoting sustainability. By enabling on-site ammonia synthesis under flexible conditions, Tsubame BHB helps clients lower their transportation and storage costs, contributing to a more efficient and sustainable ammonia supply chain.
Cambrooke Therapeutics
Acquisition in 2017
Cambrooke Therapeutics specializes in the development and manufacture of innovative clinical nutrition products designed for patients with specialized dietary needs. The company focuses on providing natural intact protein products that address the dietary management requirements of individuals with metabolic disorders, renal diseases, and phenylketonuria. By offering patient-centered therapeutic nutrition, Cambrooke Therapeutics aims to enhance the dietary experiences of those who require medical supervision for their nutritional intake, ensuring effective treatment for conditions that hinder the breakdown of specific amino acids.
Tsubame BHB
Funding Round in 2017
Tsubame BHB Co., Ltd., founded in 2017 and based in Tokyo, Japan, specializes in the research, development, and manufacturing of on-site ammonia production systems and catalysts. The company aims to commercialize ammonia production using an innovative electride catalyst in small-scale plants. This technology addresses critical environmental and food-related issues while promoting sustainability. By enabling on-site ammonia synthesis under flexible conditions, Tsubame BHB helps clients lower their transportation and storage costs, contributing to a more efficient and sustainable ammonia supply chain.
Hinoman
Series B in 2017
Hinoman is dedicated to addressing the growing global demand for healthy and sustainable food through its innovative cultivation of the all-natural plant known as mankai. This proprietary plant is rich in protein, vitamins, and other essential nutrients, making it suitable for various food products such as protein shakes, smoothies, salads, and beverages. By employing advanced precision agriculture techniques, Hinoman not only ensures the nutritional quality of its offerings but also promotes scalability and reduced environmental impact. The company's commitment to providing safe and nutritious food sources aligns with its mission to enhance global food security and sustainability.
GeneDesign
Acquisition in 2016
GeneDesign, Inc. is an oligonucleotide manufacturer based in Osaka, Japan, specializing in the synthesis of DNA, RNA, and LNA oligonucleotides at scales ranging from micro moles to grams. Founded in 2000, the company has developed a strong capability in producing nucleic acid drugs and offers research services to support pharmaceutical development. By providing high-quality products and services, GeneDesign enables its clients to advance their research and drug development efforts. As of December 31, 2016, GeneDesign operates as a subsidiary of Ajinomoto Co., Inc.
Orgen
Acquisition in 2016
Orgen Gida Sanayi ve Ticaret is a food company that specializes in the production of seasonings and packaged food products. The company focuses on delivering a variety of culinary ingredients designed to enhance the flavor of various dishes. By offering a range of products, Orgen aims to meet the diverse needs of consumers in the food industry.
Promasidor
Secondary Market in 2016
Promasidor, established in 1979 by Robert Rose, is a prominent food and beverage corporation headquartered in Cramerview, South Africa. The company manufactures and distributes a wide array of products across 36 African countries, with primary operations in Nigeria, the Democratic Republic of Congo, Ghana, Algeria, and Angola. Promasidor's product portfolio includes powdered beverages, flavor seasonings, powdered milk, cereals, and other food items, aiming to provide nutritious options for families continent-wide.
Windsor Foods
Acquisition in 2014
Windsor Foods is a prominent manufacturer and marketer of frozen ethnic foods and appetizers, headquartered in Houston, Texas. The company specializes in a diverse range of culinary offerings, including Italian cuisine, Pan-Asian appetizers, Southwestern comfort foods, and Mexican mainstays. With a commitment to maintaining high-quality standards in frozen food production, Windsor Foods has established a strong reputation in the market, supported by a rich heritage of 250 years. The company aims to provide clients with a single source for a variety of international dishes that are convenient and easy to serve, ensuring customer satisfaction through a focus on quality and service.
Althea Technologies
Acquisition in 2013
Althea Technologies specializes in contract manufacturing services for the pharmaceutical and biotechnology sectors. The company provides gene expression analysis through its eXpress Profiling technology and quantitative PCR testing services. Additionally, Althea Technologies offers cGMP drug product filling in vials and syringes, as well as the production of microbial-derived recombinant proteins and plasmid DNA. With its focus on high-quality manufacturing and innovative analytical services, Althea Technologies serves a critical role in the development and supply of biopharmaceutical products.
Somite
Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders. Incorporated in Oct. 2023, Somite.ai has raised over $10m to date.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.